title: Hydrogen sulfide attenuates doxorubicin‑induced cardiotoxicity by inhibiting calreticulin expression in H9c2 cells.
abstract: Doxorubicin (DOX) is a potent and currently available antitumor therapeutic agent; however, its clinical application is limited by the occurrence of cardiotoxicity. Preliminary evidence indicates that hydrogen sulfide (H2S) may exert protective effects against DOX cardiotoxicity. Therefore, the aim of the present study was to investigate whether calreticulin (CRT) is involved in the cardioprotection of H2S against DOX‑induced cardiotoxicity. DOX was observed to markedly induce injuries, including cytotoxicity and apoptosis, and also enhance the expression level of CRT. Notably, pretreatment of H9c2 cells with sodium hydrosulfide (a donor of H2S) significantly attenuated the decreased cell viability, the increased apoptosis rate and the increased expression level of CRT in H9c2 cells. In addition, pretreatment of H9c2 cells with N‑acetyl‑L‑cysteine, a scavenger of reactive oxygen species (ROS) prior to exposure to DOX, markedly decreased the expression of CRT. These results indicate that exogenous H2S attenuates DOX‑induced cardiotoxicity by inhibiting CRT expression in H9c2 cardiac cells.
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Mi-Hua
authors.initials: MH
authors.lastname: Liu
authors.affiliation: Department of Pathology, Mawangdui Hospital, Changsha, Hunan 410016, P.R. China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Pathology, The Third People's Hospital of Huizhou, Huizhou, Guangdong 516002, P.R. China.
authors.forename: Xiao-Long
authors.initials: XL
authors.lastname: Lin
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: He
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Tian-Ping
authors.initials: TP
authors.lastname: Tan
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Shao-Jian
authors.initials: SJ
authors.lastname: Wu
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Shan
authors.initials: S
authors.lastname: Yu
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Yu-Dan
authors.initials: YD
authors.lastname: Chen
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Hong-Yun
authors.initials: HY
authors.lastname: Fu
authors.affiliation: Department of Cardiology, The First Hospital of Changsha, Changsha, Hunan 410005, P.R. China.
authors.forename: Cong
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Department of Ultrasonic Diagnosis, Boai Hospital of Zhongshan, Zhongshan, Guangdong 528403, P.R. China.
authors.forename: Jian
authors.initials: J
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D037282:Calreticulin / Q000235:genetics*; D066126:Cardiotoxicity; D002460:Cell Line; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D006862:Hydrogen Sulfide / Q000494:pharmacology*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D037282:Calreticulin; D004317:Doxorubicin; D006862:Hydrogen Sulfide